Drug Topics June 18, 2024
Killian Meara

Sam Clark, MD, PhD, founder and CEO of Terran Biosciences, discusses what the future looks like for psychedelic treatments.

The FDA’s Psychopharmacologic Drugs Advisory Committee voted against the use of MDMA to treat PTSD earlier this month, giving proponents of psychedelic treatments a disappointing setback. The panel, which raised various concerns about a new drug application from Lykos Therapeutics, was the first to review a psychedelic-assisted therapy in the United States. The panel’s decision has left many wondering what the future of psychedelic medicine now looks like.

Drug Topics sat down with Sam Clark, MD, PhD, founder and CEO of Terran Biosciences, to discuss how the FDA advisory panel’s decision could impact the future of psychedelic medicine, if the decision...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Interview / Q&A, Mental Health, Pharma, Pharma / Biotech, Provider, Trends
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article